TWI644920B - 展現gip受體活性之胰高血糖素類似物 - Google Patents

展現gip受體活性之胰高血糖素類似物 Download PDF

Info

Publication number
TWI644920B
TWI644920B TW102121585A TW102121585A TWI644920B TW I644920 B TWI644920 B TW I644920B TW 102121585 A TW102121585 A TW 102121585A TW 102121585 A TW102121585 A TW 102121585A TW I644920 B TWI644920 B TW I644920B
Authority
TW
Taiwan
Prior art keywords
amino acid
peptide
alkyl
glucagon
acid
Prior art date
Application number
TW102121585A
Other languages
English (en)
Chinese (zh)
Other versions
TW201402603A (zh
Inventor
理查D 迪瑪奇
大衛L 席邁里
孔拉德 布萊赫
艾瑞克 吉塔斯
Original Assignee
美商印第安納大學科技研究公司
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商印第安納大學科技研究公司, 瑞士商赫孚孟拉羅股份公司 filed Critical 美商印第安納大學科技研究公司
Publication of TW201402603A publication Critical patent/TW201402603A/zh
Application granted granted Critical
Publication of TWI644920B publication Critical patent/TWI644920B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
TW102121585A 2012-06-21 2013-06-18 展現gip受體活性之胰高血糖素類似物 TWI644920B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261662874P 2012-06-21 2012-06-21
US61/662,874 2012-06-21
US201361787973P 2013-03-15 2013-03-15
US61/787,973 2013-03-15

Publications (2)

Publication Number Publication Date
TW201402603A TW201402603A (zh) 2014-01-16
TWI644920B true TWI644920B (zh) 2018-12-21

Family

ID=48692696

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102121585A TWI644920B (zh) 2012-06-21 2013-06-18 展現gip受體活性之胰高血糖素類似物

Country Status (30)

Country Link
US (2) US9868772B2 (enExample)
EP (1) EP2864350B1 (enExample)
JP (1) JP6300239B2 (enExample)
KR (1) KR20150039748A (enExample)
CN (1) CN104583233B (enExample)
AR (1) AR091478A1 (enExample)
AU (1) AU2013277372B2 (enExample)
BR (1) BR112014031671A2 (enExample)
CA (1) CA2877127A1 (enExample)
CL (1) CL2014003421A1 (enExample)
CO (1) CO7170125A2 (enExample)
CR (1) CR20150015A (enExample)
DK (1) DK2864350T3 (enExample)
EA (1) EA029025B1 (enExample)
ES (1) ES2674946T3 (enExample)
HR (1) HRP20180936T1 (enExample)
HU (1) HUE039267T2 (enExample)
IL (1) IL236386B (enExample)
MX (1) MX356000B (enExample)
MY (1) MY185217A (enExample)
PE (1) PE20150863A1 (enExample)
PH (1) PH12014502857A1 (enExample)
PL (1) PL2864350T3 (enExample)
PT (1) PT2864350T (enExample)
RS (1) RS57347B1 (enExample)
SG (1) SG11201408491SA (enExample)
SI (1) SI2864350T1 (enExample)
TR (1) TR201808818T4 (enExample)
TW (1) TWI644920B (enExample)
WO (1) WO2013192130A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56395B1 (sr) 2012-04-26 2017-12-29 Bristol Myers Squibb Co Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za lečenje agregacije trombocita
KR20150039748A (ko) * 2012-06-21 2015-04-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Gip 수용체 활성을 나타내는 글루카곤의 유사체들
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CA2895875A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives
MX373436B (es) 2013-05-28 2020-04-30 Scohia Pharma Inc Compuesto peptidico.
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
US10137170B2 (en) 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
TW201625670A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
MA55068A (fr) 2014-10-24 2022-01-05 Merck Sharp & Dohme Co-agonistes des récepteurs du glucagon et du glp-1
CN107636009B (zh) 2014-12-30 2021-04-16 韩美药品株式会社 具有改善的稳定性的胰高血糖素衍生物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TWI713541B (zh) 2015-06-30 2020-12-21 南韓商韓美藥品股份有限公司 升糖素衍生物及包含該衍生物之長效接合物之組成物
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
EA201891469A1 (ru) 2015-12-23 2018-12-28 Дзе Джонс Хопкинс Юниверсити Агонист длительного действия glp-1r как терапия для лечения неврологических и нейродегенеративных патологических состояний
HUE059737T2 (hu) * 2015-12-31 2022-12-28 Hanmi Pharm Ind Co Ltd Glükagon, GLP-1 és GIP receptor aktiváló tripla aktivátor
CN109477094B (zh) 2016-05-24 2022-04-26 武田药品工业株式会社 肽化合物
PE20190355A1 (es) 2016-06-29 2019-03-07 Hanmi Pharm Ind Co Ltd Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
CN120887972A (zh) * 2017-11-24 2025-11-04 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物
HUE059777T2 (hu) 2018-04-10 2022-12-28 Sanofi Aventis Deutschland Lixiszenatid szintézise lánczárással
AU2019250359B2 (en) 2018-04-10 2025-12-18 Sanofi-Aventis Deutschland Gmbh Method for cleavage of solid phase-bound peptides from the solid phase
CA3097939A1 (en) 2018-05-04 2019-11-07 Novo Nordisk A/S Gip derivatives and uses thereof
TW202015735A (zh) 2018-05-30 2020-05-01 法商賽諾菲公司 包含glp-1/升糖素/gip三重受體促效劑、連接子及透明質酸之接合物
KR102351313B1 (ko) * 2018-07-23 2022-01-17 일라이 릴리 앤드 캄파니 Gip/glp1 공효능제 화합물
US11166910B2 (en) 2019-01-25 2021-11-09 Nordiccan A/S Cannabinoid chewing gum with sugar alcohols
EP4112637A4 (en) * 2020-02-24 2024-04-03 Shenzhen Turier Biotech Co., Ltd. POLYPEPTIDE COMPOUND AND ITS APPLICATION IN THE PREVENTION OR TREATMENT OF DIABETES OR A COMPLICATION OF DIABETES
JP2023519446A (ja) * 2020-03-25 2023-05-10 武田薬品工業株式会社 Gip受容体アゴニストペプチド化合物のqd投薬及びその使用
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
KR102446310B1 (ko) 2020-07-22 2022-09-23 노보 노르디스크 에이/에스 경구 전달에 적합한 glp-1 및 gip 수용체에서의 공-작용제
CN114621327B (zh) * 2020-12-10 2023-08-18 江苏中新医药有限公司 GLP-1、GIP和Gcg多重受体激动蛋白质
WO2022133797A1 (zh) 2020-12-23 2022-06-30 浙江道尔生物科技有限公司 一种长效胰高血糖素衍生物
CN117120462A (zh) * 2021-01-22 2023-11-24 深圳市图微安创科技开发有限公司 多肽化合物在预防或治疗炎症性肠病及其相关的肠纤维化中的应用
AU2022311018A1 (en) * 2021-07-16 2024-01-25 Pep2Tango Therapeutics Inc. Compositions including multi-agonist peptides and methods of manufacture and use
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN115490760B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物
JP7402574B1 (ja) 2023-03-15 2023-12-21 株式会社合同資源 α-ヨード置換カルボン酸

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155258A2 (en) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2011163012A2 (en) * 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗hiv剤
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
DE60331455D1 (de) 2002-10-04 2010-04-08 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
CA2651283A1 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
MX2009008241A (es) * 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
RU2422134C1 (ru) 2007-04-19 2011-06-27 Донг-А Фармасьютикал. Ко., Лтд Композиция биоразлагающихся микросфер, пригодная для контролируемого высвобождения контролирующего уровень глюкозы пептида, и ее состав
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
WO2010011439A2 (en) * 2008-06-17 2010-01-28 Indiana University Research And Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
JP6121323B2 (ja) * 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
JP6179864B2 (ja) * 2011-06-22 2017-08-16 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン/glp−1レセプタコ−アゴニスト
CN103748109A (zh) * 2011-06-22 2014-04-23 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共同激动剂
KR20150039748A (ko) * 2012-06-21 2015-04-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Gip 수용체 활성을 나타내는 글루카곤의 유사체들
EP3206710B1 (en) * 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Incretin-insulin conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155258A2 (en) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2011163012A2 (en) * 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs

Also Published As

Publication number Publication date
EP2864350A1 (en) 2015-04-29
JP2015528795A (ja) 2015-10-01
MY185217A (en) 2021-04-30
SI2864350T1 (en) 2018-08-31
PT2864350T (pt) 2018-05-14
MX2014015556A (es) 2015-03-05
PL2864350T3 (pl) 2019-01-31
CN104583233A (zh) 2015-04-29
CL2014003421A1 (es) 2015-05-22
ES2674946T3 (es) 2018-07-05
KR20150039748A (ko) 2015-04-13
PH12014502857A1 (en) 2015-02-23
RS57347B1 (sr) 2018-08-31
CN104583233B (zh) 2018-10-23
CR20150015A (es) 2015-04-24
IL236386A0 (en) 2015-02-26
US20150368310A1 (en) 2015-12-24
US20180105569A1 (en) 2018-04-19
TR201808818T4 (tr) 2018-07-23
TW201402603A (zh) 2014-01-16
US9868772B2 (en) 2018-01-16
EA201590065A1 (ru) 2015-07-30
CO7170125A2 (es) 2015-01-28
CA2877127A1 (en) 2013-12-27
AU2013277372A1 (en) 2014-12-11
BR112014031671A2 (pt) 2018-08-07
PE20150863A1 (es) 2015-06-11
JP6300239B2 (ja) 2018-03-28
IL236386B (en) 2019-09-26
EP2864350B1 (en) 2018-03-28
SG11201408491SA (en) 2015-01-29
WO2013192130A1 (en) 2013-12-27
HRP20180936T1 (hr) 2018-12-14
MX356000B (es) 2018-05-08
DK2864350T3 (en) 2018-05-28
EA029025B1 (ru) 2018-01-31
AU2013277372B2 (en) 2018-03-29
AR091478A1 (es) 2015-02-04
HUE039267T2 (hu) 2018-12-28

Similar Documents

Publication Publication Date Title
TWI644920B (zh) 展現gip受體活性之胰高血糖素類似物
TWI599575B (zh) 表現gip受體活性之胰高血糖素類似物
JP6086067B2 (ja) Gipレセプター活性を示すグルカゴンアナローグ
TWI501775B (zh) 升糖素/glp-1受體共促效劑
JP6179864B2 (ja) グルカゴン/glp−1レセプタコ−アゴニスト
JP6184404B2 (ja) グルカゴン/glp−1レセプターコアゴニスト

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees